Omalizumab
ATC Code
R03DX05
Omalizumab
Definition
A humanized monoclonal antibody directed against the C-epsilon 3 domain of immunoglobulin E. Olizumab binds to this IgE domain, thereby preventing IgE from binding to its high-affinity mast-cell receptor. (NCI04)
Also known as Anti-IgE Monoclonal Antibody E25, IGE 025, Olizumab, OMALIZUMAB, rhuMAb-E25, Xolair — per NCIT
Also identified as
- ATC R03DX05 per RXNORM
- NCIT NCIT:C29299 per NCIT
- SCTID 406442003 per RXNORM
- SCTID 406443008 per RXNORM
- UNII 2P471X1Z11 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Asthma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Respiratory system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.